General Information of Drug (ID: DMHIBTZ)

Drug Name
PMID29130358-Compound-Figure18(14a) Drug Info
Cross-matching ID
TTD Drug ID
DMHIBTZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [4]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [1]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [1]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [6]
MMI270 DM38N2K Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [10]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [1]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [11]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [12]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [6]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [13]
SC-44463 DMBPNKT N. A. N. A. Terminated [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [15]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [16]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [17]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [18]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [19]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [20]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [1]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [1]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [21]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [20]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [22]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [1]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [1]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [1]
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [1]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [1]

References

1 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
2 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
3 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
4 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
5 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
6 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
7 Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
8 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
9 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
10 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
11 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
12 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
13 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
14 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
15 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
16 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
17 National Cancer Institute Drug Dictionary (drug id 747683).
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
20 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
21 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
22 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.